Beone Medicines USA, INC. (FKA Beigene USA, INC.)
Biopharmaceutical company.
Based in MA
🤖
AI Overview
With $1.7M in lobbying spend across 28 quarterly filings, Beone Medicines USA, INC. (FKA Beigene USA, INC.) is a significant lobbying presence.
$1.7M
Total Lobbying Spend
28
Quarterly Filings
1
Lobbying Firms Used
8
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2020 | $40K |
| 2021 | $480K |
| 2022 | $420K |
| 2023 | $280K |
| 2024 | $280K |
| 2025 | $210K |
Lobbying Firms
TIBER CREEK GROUP
What They Lobby For
- Monitoring activities related to trade
- Monitoring activities related to drug policy
- Monitoring activities related to drug policy.
- Monitoring activities related to trade.
- Issues relating to Part D pricing reform; Issues relating to Part B pricing reform.
- Issues related to pharmaceutical pricing and transparency.
- Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
- Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization.
- Issues relating to US and international manufacturing.
- Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials.
Related Investigations
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.